Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning tablets for coronary heart disease via gut microbiota regulation
ChiCTR2500097864Phase 4Not yet recruiting
- Sponsor
- Shuguang Hospital
- Start
- Feb 2025
- Countries
- 1
01
Overview
Phase 4, open-label trial of Guanxinning in coronary arteriosclerosis (2 arms), sponsored by Shuguang Hospital. Primary endpoint: 16S sequencing of gut microbiota. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
Guanxinning
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500097864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097864.